In people at high risk for type 1 diabetes, 14 days of therapy with the experimental drug teplizumab delayed development of the disease by a year or more.

For six weeks seven-year-old Bethan Westcott-Storer was feeling listless and losing weight, worrying parents Lizzie and Dean. Now aged nine, she’s the picture of health, having been diagnosed with type 1 diabetes in November 2014, since when she’s been treating herself via an omnipod pump that delivers insulin via a cannula under her skin. “I […]